methamphetamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1732 537-46-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • methamphetamine
  • (S)-Methamphetamine
  • methylamphetamine
  • D-Methylamphetamine
  • methamphetamine hydrochloride
  • metamfetamine
  • methamphetamine HCl
A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.
  • Molecular weight: 149.24
  • Formula: C10H15N
  • CLOGP: 1.89
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 1
  • TPSA: 12.03
  • ALOGS: -2.21
  • ROTB: 3
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
15 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 0 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1000 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 40 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.92 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 67 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 4.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.85 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 12 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 31, 1943 FDA RECORDATI RARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 3031.21 53.53 694 2409 59152 50542869
Toxicity to various agents 1029.43 53.53 406 2697 212093 50389928
Completed suicide 436.24 53.53 194 2909 131695 50470326
Cardio-respiratory arrest 218.62 53.53 92 3011 53800 50548221
Respiratory arrest 183.65 53.53 69 3034 29940 50572081
Cardiac arrest 179.95 53.53 92 3011 83559 50518462
Death 159.08 53.53 142 2961 325237 50276784
Overdose 65.76 53.53 52 3051 99675 50502346
Amphetamines positive 59.17 53.53 10 3093 152 50601869
Substance abuse 59.08 53.53 18 3085 4106 50597915

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 4457.23 56.25 1239 4058 78644 29490586
Toxicity to various agents 1689.73 56.25 741 4556 172920 29396310
Completed suicide 307.30 56.25 194 5103 90052 29479178
Respiratory arrest 263.53 56.25 116 5181 25717 29543513
Cardio-respiratory arrest 234.79 56.25 133 5164 50468 29518762
Cardiac arrest 179.80 56.25 137 5160 85454 29483776
Exposure to toxic agent 143.60 56.25 41 5256 2534 29566696
Death 131.54 56.25 225 5072 341859 29227371
Overdose 117.44 56.25 104 5193 79715 29489515
Respiratory depression 92.03 56.25 46 5251 13477 29555753
Pulmonary oedema 86.34 56.25 67 5230 42668 29526562
Drug abuser 84.13 56.25 30 5267 3797 29565433
Incorrect route of product administration 83.23 56.25 40 5257 10761 29558469
Brain oedema 75.65 56.25 39 5258 12181 29557049
Accidental overdose 75.31 56.25 44 5253 17549 29551681
Intentional product misuse 64.93 56.25 52 5245 34609 29534621
Substance abuse 64.28 56.25 29 5268 6758 29562472
Pulmonary congestion 60.99 56.25 34 5263 12402 29556828
Amphetamines positive 60.72 56.25 12 5285 145 29569085
Drug screen positive 58.69 56.25 23 5274 3778 29565452

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 7181.31 47.61 1870 6338 130504 64360020
Toxicity to various agents 2713.47 47.61 1163 7045 362350 64128174
Completed suicide 671.52 47.61 392 7816 224022 64266502
Cardio-respiratory arrest 463.71 47.61 233 7975 98160 64392364
Respiratory arrest 433.06 47.61 184 8024 52801 64437723
Cardiac arrest 338.89 47.61 222 7986 153842 64336682
Death 309.76 47.61 341 7867 482364 64008160
Overdose 191.79 47.61 160 8048 159406 64331118
Exposure to toxic agent 188.32 47.61 57 8151 6102 64484422
Respiratory depression 157.31 47.61 71 8137 23372 64467152
Intentional product misuse 145.91 47.61 99 8109 72196 64418328
Accidental overdose 144.51 47.61 75 8133 33482 64457042
Pulmonary oedema 115.85 47.61 89 8119 78585 64411939
Incorrect route of product administration 105.84 47.61 54 8154 23244 64467280
Amphetamines positive 103.20 47.61 19 8189 222 64490302
Drug abuser 100.83 47.61 35 8173 5773 64484751
Substance abuse 95.12 47.61 38 8170 9254 64481270
Drug screen positive 86.03 47.61 31 8177 5698 64484826
Opiates positive 83.44 47.61 20 8188 878 64489646
Pulmonary congestion 79.43 47.61 45 8163 23835 64466689
Brain oedema 66.49 47.61 39 8169 22036 64468488
Poisoning 64.18 47.61 38 8170 21841 64468683
Fatigue 63.19 47.61 10 8198 748720 63741804
Diarrhoea 62.48 47.61 9 8199 722695 63767829
Drug ineffective 59.16 47.61 17 8191 840230 63650294
Postmortem blood drug level 52.66 47.61 11 8197 255 64490269
Accidental poisoning 51.14 47.61 15 8193 1438 64489086
Pyrexia 50.52 47.61 6 8202 558638 63931886
Drug interaction 50.30 47.61 129 8079 361954 64128570
Nausea 48.20 47.61 20 8188 785780 63704744
Accidental death 47.96 47.61 18 8190 3707 64486817

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06BA03 NERVOUS SYSTEM
PSYCHOANALEPTICS
PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
Centrally acting sympathomimetics
FDA CS M0001015 Amphetamines
FDA PE N0000175372 Appetite Suppression
FDA EPC N0000175425 Amphetamine Anorectic
MeSH PA D018663 Adrenergic Agents
MeSH PA D018759 Adrenergic Uptake Inhibitors
MeSH PA D002491 Central Nervous System Agents
MeSH PA D000697 Central Nervous System Stimulants
MeSH PA D015259 Dopamine Agents
MeSH PA D018765 Dopamine Uptake Inhibitors
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D013566 Sympathomimetics
CHEBI has role CHEBI:35337 analeptic
CHEBI has role CHEBI:35471 psychotropic drugs
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:50910 agente neurotoxico
CHEBI has role CHEBI:78298 environmental contaminants
FDA PE N0000175651 Increased Sympathetic Activity
FDA PE N0000175729 Central Nervous System Stimulation
FDA EPC N0000175739 Central Nervous System Stimulant

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Attention deficit hyperactivity disorder indication 406506008
Obesity indication 414916001 DOID:9970
Gilles de la Tourette's syndrome contraindication 5158005 DOID:11119
Suicidal thoughts contraindication 6471006
Dependent drug abuse contraindication 6525002
Alcoholism contraindication 7200002
Hyperammonemia contraindication 9360008
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Bipolar disorder contraindication 13746004 DOID:3312
Hepatic encephalopathy contraindication 13920009 DOID:13413
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Feeling agitated contraindication 24199005
Hyperthyroidism contraindication 34486009 DOID:7998
Depressive disorder contraindication 35489007
Hypertensive disorder contraindication 38341003 DOID:10763
Hyperactive behavior contraindication 44548000
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Anorexia nervosa contraindication 56882008 DOID:8689
Hepatic failure contraindication 59927004
Aggressive behavior contraindication 61372001
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Arteriosclerotic vascular disease contraindication 72092001
Hepatic coma contraindication 72836002 DOID:12550
Sleep apnea contraindication 73430006 DOID:0050847
Cardiomyopathy contraindication 85898001 DOID:0050700
Weight loss contraindication 89362005
Kidney disease contraindication 90708001 DOID:557
Structural disorder of heart contraindication 128599005
Seizure disorder contraindication 128613002
Motor tic disorder contraindication 230337001
Cerebrovascular accident contraindication 230690007
Mania contraindication 231494001
Disease of liver contraindication 235856003 DOID:409
Sleep automatism contraindication 247962006
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Cardiovascular event risk contraindication 395112001
Visual impairment contraindication 397540003
Respiratory insufficiency contraindication 409623005
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Porphyria contraindication 418470004
Hypertensive urgency contraindication 443482000
Acute exacerbation of asthma contraindication 708038006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.73 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium-dependent dopamine transporter Transporter INHIBITOR Ki 7.61 PDSP CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 5.08 CHEMBL
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 6.13 PDSP
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Ki 7.91 PDSP
5-hydroxytryptamine receptor 2B GPCR Ki 5 PDSP
Alpha-2B adrenergic receptor GPCR Ki 6.13 PDSP
Alpha-2C adrenergic receptor GPCR Ki 6.09 PDSP
Trace amine-associated receptor 1 GPCR AGONIST EC50 5.89 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 5.38 PDSP
Synaptic vesicular amine transporter Transporter Ki 5.61 CHEMBL
Trace amine-associated receptor 1 GPCR EC50 5.28 CHEMBL
Trace amine-associated receptor 1 GPCR EC50 6.88 CHEMBL
Trace amine-associated receptor 1 GPCR EC50 7.15 CHEMBL

External reference:

IDSource
4019821 VUID
N0000147910 NUI
D02242 KEGG_DRUG
51-57-0 SECONDARY_CAS_RN
4018483 VANDF
4019821 VANDF
C0025611 UMLSCUI
CHEBI:6809 CHEBI
B40 PDB_CHEM_ID
CHEMBL1201201 ChEMBL_ID
DB01577 DRUGBANK_ID
CHEMBL1200952 ChEMBL_ID
D008694 MESH_DESCRIPTOR_UI
10836 PUBCHEM_CID
1879 INN_ID
4803 IUPHAR_LIGAND_ID
44RAL3456C UNII
6816 RXNORM
1988 MMSL
5066 MMSL
d00805 MMSL
001797 NDDF
004722 NDDF
387329009 SNOMEDCT_US
387499002 SNOMEDCT_US
8692006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Methamphetamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-0389 TABLET 5 mg ORAL ANDA 25 sections
Desoxyn HUMAN PRESCRIPTION DRUG LABEL 1 55292-102 TABLET 5 mg ORAL NDA 25 sections
Desoxyn HUMAN PRESCRIPTION DRUG LABEL 1 55292-104 TABLET 5 mg ORAL NDA 25 sections
Methamphetamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68308-115 TABLET 5 mg ORAL ANDA 29 sections
Methamphetamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68308-115 TABLET 5 mg ORAL ANDA 29 sections